TrialDrugs in R&D2023

A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin

Jing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.